Previous 10 | Next 10 |
2024-01-14 03:44:11 ET Summary Syros Pharmaceuticals is a cancer-focused biotech working on therapies for blood cancer, with a main drug in development. The company's main program is tamibarotene, targeting specific myeloid cancers with high RARA gene expression. Syros has enc...
-- On-Track to Complete Enrollment of 190 patients for Primary Analysis in SELECT-MDS-1 Phase 3 Trial in 1Q 2024; Pivotal CR Data Expected by Mid-4Q 2024 -- -- Additional Data from SELECT-AML-1 Phase 2 Trial Expected in 2024; Initial Data Demonstrated 100% CR/CRi Rate and Favorable Tolera...
2023-12-27 02:04:59 ET More on Syros Pharmaceuticals Syros prices capital raise of $45.0 million via securities offering Syros jumps after Phase 2 data for leukemia therapy Seeking Alpha’s Quant Rating on Syros Pharmaceuticals For further details see: ...
2023-12-27 02:04:59 ET More on Syros Pharmaceuticals Syros prices capital raise of $45.0 million via securities offering Syros jumps after Phase 2 data for leukemia therapy Seeking Alpha’s Quant Rating on Syros Pharmaceuticals For further details see: ...
2023-12-19 07:49:27 ET More on Syros Pharmaceuticals Syros jumps after Phase 2 data for leukemia therapy Syros Pharmaceuticals GAAP EPS of -$1.43 misses by $0.29, revenue of $3.76M misses by $0.18M Seeking Alpha’s Quant Rating on Syros Pharmaceuticals ...
Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, announced today that it has priced an underwritten offering of 4,939,591 shares of common stock at an offering price of $4.42 per...
2023-12-06 17:29:59 ET DENVER, Colo., Dec. 6, 2023 ( www.247marketnews.com )- The following companies published announcements or traded higher-than-usual volume; Sera Prognostics Inc (NASDAQ: SERA), MicroAlgo Inc (NASDAQ: MLGO), Syros Pharmaceuticals Inc (NASDAQ: SYRS), Altimmune Inc (N...
2023-12-06 13:46:53 ET Syros Pharmaceuticals ( NASDAQ: SYRS ) added ~41% on Wednesday after the Massachusetts area biotech disclosed early data from a Phase 2 trial evaluating its oral leukemia drug, tamibarotene, as a combination therapy. Based on data from 19 pat...
2023-12-06 12:41:58 ET More on Mid-day movers $ stocks. Altimmune: Don't Buy The GLP-1 Move-Up Altimmune: Pemvidutide Data Reinforces Obesity Drug Outlook Syros Pharmaceuticals, Inc. (SYRS) Q3 2023 Earnings Call Transcript Altimmune weight-loss drug performed...
2023-12-06 12:33:41 ET DENVER, Colo., Dec. 6, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual midday volume; Sera Prognostics Inc (NASDAQ: SERA), MicroAlgo Inc (NASDAQ: MLGO), Kamada Ltd (NASDAQ: KMDA), Syros Pha...
News, Short Squeeze, Breakout and More Instantly...
Syros Pharmaceuticals Inc. Company Name:
SYRS Stock Symbol:
NASDAQ Market:
Syros Pharmaceuticals Inc. Website:
-- Pivotal Complete Response (CR) Data from SELECT-MDS-1 Phase 3 Trial Expected by Mid-4Q24 -- -- Additional Data from SELECT-AML-1 Phase 2 Trial Expected in September 2024-- -- Management to Host Conference Call at 8:30 AM ET Today -- Syros Pharmaceuticals (NA...
Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Wednesday, July 31, 2024 to report its s...
2024-07-19 10:10:00 ET July 19, 2024 (Investorideas.com Newswire) Investorideas.com , a global news source and expert investing resource, announces today's roundup of stocks to watch in the Biotech, Cleantech Sectors. The newest biotech companies are involved in blood disorder treat...